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Abstract
Background: Pilocytic Astrocytomas (PAs) are common low-grade central nervous system malignancies for which
few recurrent and specific genetic alterations have been identified. In an effort to better understand the molecular
biology underlying the pathogenesis of these pediatric brain tumors, we performed higher-order transcriptional
network analysis of a large gene expression dataset to identify gene regulatory pathways that are specific to this
tumor type, relative to other, more aggressive glial or histologically distinct brain tumours.
Methods: RNA derived from frozen human PA tumours was subjected to microarray-based gene expression
profiling, using Affymetrix U133Plus2 GeneChip microarrays. This data set was compared to similar data sets
previously generated from non-malignant human brain tissue and other brain tumour types, after appropriate
normalization.
Results: In this study, we examined gene expression in 66 PA tumors compared to 15 non-malignant cortical brain
tissues, and identified 792 genes that demonstrated consistent differential expression between independent sets of
PA and non-malignant specimens. From this entire 792 gene set, we used the previously described PAP tool to
assemble a core transcriptional regulatory network composed of 6 transcription factor genes (TFs) and 24 target
genes, for a total of 55 interactions. A similar analysis of oligodendroglioma and glioblastoma multiforme (GBM)
gene expression data sets identified distinct, but overlapping, networks. Most importantly, comparison of each of
the brain tumor type-specific networks revealed a network unique to PA that included repressed expression of
ONECUT2, a gene frequently methylated in other tumor types, and 13 other uniquely predicted TF-gene
interactions.
Conclusions: These results suggest specific transcriptional pathways that may operate to create the unique
molecular phenotype of PA and thus opportunities for corresponding targeted therapeutic intervention. Moreover,
this study also demonstrates how integration of gene expression data with TF-gene and TF-TF interaction data is a
powerful approach to generating testable hypotheses to better understand cell-type specific genetic programs
relevant to cancer.
Background
Novel, albeit limited, insights into the molecular basis of
human disease have resulted from the use of high-reso-
lution, microarray-based platforms to comprehensively
study complex diseases at multiple levels of the genetic
program. For example, in central nervous system (CNS)
tumors, array-based comparative genomic hybridization
(aCGH) and DNA sequencing have led to the
identification of tumor-associated chromosomal gains
and losses and the corresponding specific gene muta-
tions within these altered loci [1-3]. Gene expression-
based studies have also profiled thousands of individual
transcriptional units to uncover novel genes whose
expression is de-regulated, concordant with other clini-
cal features of these tumors, such as histological grade
and patient survival [4-6]. The combined use of both
technologies has identified individual genetic biomarkers
associated with CNS tumorigenesis and tumor behavior,
although few have yet resulted in specific strategies for
targeted drug therapy [7].
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The accumulation of ‘genome-wide’ data sets from
CNS tumors is demonstrating that the processes of
tumorigenesis and tumor progression likely involve the
coordinated de-regulation of entire molecular networks,
rather than single genes. Therefore, mutation, altered
copy number, and abnormal expression of single genes
observed to vary across individual tumors may be better
viewed collectively to identify underlying commonalities
at the level of molecular programs, based on known
protein-protein interactions, canonical cell signaling
pathways, and in silico transcriptional regulatory control
predictions. As opposed to identifying single gene/pro-
tein targets for anti-cancer drug design, these networks
establish broader, multi-target pathways for therapeutic
intervention. The combination of higher-order DNA-
and RNA-based microarray meta-analyses offers the
potential to discover these therapeutically-relevant net-
works [8].
Pilocytic Astrocytomas (PAs) are World Health Orga-
nization (WHO) grade I glial CNS tumors, accounting
for one-fifth of all central nervous system tumors. How-
ever, in young children and adolescents, PAs are the
most common brain tumor. Compared to other high-
grade CNS gliomas, such as Glioblastoma Multiforme
(GBM), PAs are characterized by low cell proliferative
indices, a biphasic histologic appearances, and microglial
infiltration. PAs also lack the genetic alterations
observed in high-grade glioma, and in general exhibit
few molecular alterations at the DNA level. Previous
studies have demonstrated occasional copy number
changes involving chromosomes 6, 7, 8, and 11 [9,10].
In a recent study [1], we identified genome copy num-
ber alterations occurring in cerebellar PA using aCGH
on patient-matched tumor and normal samples. How-
ever, as in other reported studies, only a limited number
of consistent genetic alterations were identified.
Current treatments for these pediatric brain tumors
include surgical resection, radiation, and chemotherapy.
However, in young children, these treatments are asso-
ciated with secondary damage to the developing brain,
and result in long term neuropsychological and neu-
roendocrine dysfunction. In addition, since children
with PA have good overall survival, it is imperative to
identify the key genetic and growth control pathways
de-regulated in the tumor and not the normal brain for
future therapeutic drug design. Given this clinical
imperative and the limited success in identifying thera-
peutic targets by conventional genomic analyses, we
employed a higher-order, network-based analytical
approach to discover subtle alterations in genetic path-
ways operative specifically in PA.
In the present study, we first identified PA-specific
gene expression signatures in a meta-analysis of 74 PA
microarray datasets. We then utilized the identity of
these genes to construct a PA-specific gene network
based on transcription factor gene regulatory interac-
tions. Moreover, we identified relationships that are
both common and specific to PAs compared to other
cell lineage-related glial tumor types by creating similar
gene regulatory networks from GBM and oligodendro-
glioma microarray datasets. Our approach has identified
a unique genetic network in PA which may account for
the novel phenotype of this brain tumor, and also
demonstrates the general utility of using network-based
approaches to analyze complex molecular profiling data
from other tumor types.
Methods
Sample and Affymetrix GeneChip processing
All studies of de-identified, previously collected (exist-
ing) frozen human tumor tissue specimens were per-
formed under an institutional reviewed and approved
human studies protocol (WU HRPO #99-0573 and
#04-0980). Frozen tumor tissues were sectioned and
histologically reviewed to confirm pathological diagno-
sis and neoplastic cellularity (AP). Serial tissue sections
was used to isolated tumor RNA using Trizol reagent
(Invitrogen, Carlsbad, CA) and following the manufac-
turer’s standard protocol. Resulting RNA was quanti-
fied by A260 and A280 readings using a Nanodrop
spectrophotometer (Nanodrop Technologies, Wilming-
ton DE) and qualitatively assessed using a BioAnalyzer
2100 and RNANanoChip assay (Agilent Technologies,
Palo Alto, CA). All histology and nucleic acid extrac-
tion procedures were performed by the Siteman Can-
cer Center Tissue Procurement Core. Microarray data
for 74 PA samples was generated with Affymetrix
U133 Plus 2.0 arrays containing 54,675 probesets in
the Siteman Cancer Center Molecular and Genomic
Analysis Core (Washington University School of Medi-
cine) starting with 1 μg of quality controlled total cel-
lular RNA and using standard laboratory and
manufacturer protocols.
Data normalization and quality review
To facilitate comparison between multiple different
datasets, meta-analysis was limited to the use of data
generated using the Affymetrix GeneChip™ expression
array platform. Data from 15 non-malignant frontal and
prefrontal cortex brain tissue samples, hereafter referred
to as non-malignant brain tissue samples, were obtained
from ArrayExpress (E-TABM-20, E-TABM-84) [11,12].
Tumor datasets for GBM and oligodendroglioma were
downloaded from GEO (GSE4412, GSE9385 and
GSE4271 (GBM and oligodendroglioma) [5,6,13]) and
The Cancer Genome Atlas (TCGA) [3]. For the
GSE9385 dataset, which used Affymetrix GeneChip
Exon arrays, non-malignant brain tissue samples that
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were also included in the dataset were used as the con-
trol set.
To perform inter-array comparisons and quality con-
trol, the raw data (i.e. CEL files) from each microarray
were scaled to a target intensity of 1500 using the Affy-
metrix Expression Console (EC) version 1.1 (MAS 5.0
algorithm). Quality control review for all microarray
data included percent present calls, RawQ, background,
scaling factor, and 3’-5’ ratios for GAPDH and beta-
actin. Affymetrix control probes and probesets that were
called “Absent” across all samples were removed. The
MAS 5.0 data were z-normalized using the mean and
standard deviation for each probe. Hierarchical agglom-
erative clustering was performed using both Spotfire’s
DecisionSite and Bioconductor software Unweighted
pair-group method with arithmetic mean (UPGMA) was
used as the clustering method, and Euclidian distance
was used to calculate similarity.
Unsupervised hierarchical clustering was first per-
formed on the entire 74 PA sample set. Clustering out-
liers and data sets which failed array quality control
parameters were removed. The 15 non-malignant brain
sample data sets were next added to the entire dataset,
and z-normalization and hierarchical clustering was
repeated. Tumor samples which segregated with non-
malignant samples were also removed from further ana-
lysis. The final dataset consisted of 66 PA tumors and
15 non-malignant brain tissue samples. On retrospective
review, the 8 PA tumor data sets excluded from analysis
were confirmed to be initially misclassified based upon
histological re-review of WHO grade I criteria for PA.
Identification of gene expression signatures
A gene expression signature that delineated PA from
non-malignant brain tissue was identified using iterative
and independent parallel data sets framework (Figure 1),
based on the Significance Analysis of Microarrays
(SAM) algorithm [14]. SAM was performed using Bio-
conductor with log2 transformed MAS 5.0 data filtered
as described above. The 66 tumor samples were ran-
domly divided into two groups of 33 samples. For the
training arm of the protocol, the first 33 samples were
randomly divided into two groups of 22 and 11. SAM
analysis was conducted for each of these groups against
the 15 non-malignant brain tissue samples. The mini-
mum fold change threshold was defined as two-fold.
Multiple testing correction was employed by setting the
delta value to the highest value for which the 90th per-
centile of the FDR distribution remained equal to zero.
Genes that were significant in both training samples
groups were recorded and the samples were then rando-
mized into two new training groups of 22 and 11 sam-
ples. This processed was repeated for 10 iterations. An
output table was generated that consisted of genes that
demonstrated consistent difference in expression in
common between the two parallel training groups, in all
10 iterations of the training loop. The testing arm of the
protocol then consisted of a single SAM analysis on the
remaining 33 tumor samples of the entire 66 sample
cohort. While it is possible that this approach may
introduce bias and has the potential for false positives in
the gene set because the test set was not resampled, the
likelihood of this is low given that ALL genes identified
in the training set were recapitulated in the test set,
thus validating the robustness of the training loop.
Furthermore, identified genes were further filtered
through network construction as described in the next
section.
To identify differentially expressed genes in other glial
tumor histological types (GBM and oligodendroglioma),
we employed the same 15 non-malignant brain tissue
sample set (except for GSE9385 where the non-malignant
controls provided in the data set were used), and a single
SAM analysis on each of the GBM and oligodendroglioma
datasets described above. Multiple datasets for GBM were
available, and each dataset was analyzed separately using
SAM to identify differentially-expressed genes.
Network analysis to create a minimal gene regulatory
network
The probe identifiers for the differentially expressed
genes (DEGs) were mapped to Entrez Gene IDs using
Affymetrix-provided Accession Numbers and annota-
tions available from NCBI’s Entrez Gene database, and
Entrez Gene IDs were used to identify transcription fac-
tors (TFs) from TRANSFAC 11.4 and JASPAR data-
bases. The Promoter Analysis Pipeline (PAP) [15] was
next employed to construct the TF-TF network (Figure
2-step 2) and the TF-target network (Figure 2-step 3). A
p-value cutoff of 0.005 was used to select TF-target
interactions from PAP. A regulatory network was
defined as a cumulative representation of all interactions
between TFs and their known target genes, one or both
of which was represented in the DEG list. In this
arrangement, therefore, a regulatory network may
encompass many branching sub-networks, even if only
one major network is of interest based upon gene
expression data. Multiple studies have found that TFs
work in conjunction with each other to regulate genes;
thus, this information was incorporated into the regula-
tory network by finding targets that are commonly regu-
lated by more than one TF (Figure 2-step 4). This
network is called a minimal network (i.e. the resulting
network where each target gene is regulated by at least
two TFs). The differential expression analysis provided
quantitative data on over-expression or under-expres-
sion of a gene in PA samples when compared to non-
malignant brain tissue samples. When overlaid on the
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regulatory network, this information provided the differ-
ence in expression of a gene in response to difference in
expression of another gene. Finally, the hypergeometric
distribution test was used to identify overrepresented
transcriptional regulatory pathways predicted by the
minimal network gene list [16].
The same approach was used to create a minimal net-
work for the oligodendroglioma dataset. Multiple GBM
datasets were used to identify differentially expressed
genes, and minimal networks were created as described
above. These individual GBM networks were pooled
together by taking the union of all relationships for each
66 Grade I
15 normal brain
33 Grade I
15 Normal brain
33 Grade I    
15 Normal brain    
22 Grade I
15 Normal brain
11 Grade I
15 Normal brain
SAMSAM
Intersect
Common Differentially Expressed Genes
Random Sampling
Random Sampling
  Loop 10 times
792 genes present
in all 10 output tables
SAM
1865
Differentially
Expressed
Genes
  Extent of Overlap
792 genes present
in both analyses
Differentially
Expressed
Genes
Differentially
Expressed
Genes
TRAINING TESTING
Figure 1 SAM-based gene selection framework employed to identify differentially expressed genes in independent sets of pilocytic
astrocytoma gene expression data.
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GBM dataset and this consolidated set was used to cre-
ate the composite GBM minimal network. Finally, while
this approach is limited to constructing a network using
only those TFs that have demonstrable differential
expression and may thus not identify all TFs and TF-
target interactions, we chose to employ the above algo-
rithm given the experimental data sets that were
employed for network construction and the desire to
construct a more robust, though perhaps incomplete,
network.
Identification of relationships in common with tumor
types and specific to PA
The pair-wise relationships generated as a result of net-
work analysis of PA and other glial tumor types allowed
the identification of relationships common across tumor
types as well as those specific to PA. A relationship was
defined as common when a relationship between two
genes that was identified in PA (based upon the DEG
list) was also present in one or more other tumor types
(GBM or oligodendroglioma). A relationship was
defined as specific to PA when the relationship was pre-
sent between two genes in PA but was not present in
any of the other glial tumor types.
Results and Discussion
Identification of PA-specific gene expression patterns
We used a relatively large sample set, divided into two
independent sets for SAM analysis (Figure 1) to identify
differentially-expressed gene transcripts which were
recurrently represented in PA samples compared to
non-malignant cortical brain tissue samples. Using this
framework, we were able to identify genes scored as ‘sig-
nificant’ (FDR = 0% by SAM) across multiple iterative
analyses using random sampling of the first PA expres-
sion dataset, and then confirm that the signature identi-
fied was also represented in a second, independent set
of tumor samples. This method was modeled on existing
supervised methods, including Support Vector Machines
and Artificial Neural Networks [17,18], and facilitated
the reliable identification of differentially-expressed
genes in the absence of large independent datasets not
currently available for PA. One recognized limitation of
this approach is that the same reference set of 15 non-
malignant brain tissue samples was used in all of the
SAM analyses. Ideally, if such material or data were
available, it would have been desirable to perform com-
parative analysis using an independent set of non-malig-
nant tissue samples, as was done for the PA samples
themselves. Second, although PAs, GBMs, and oligoden-
drogliomas could have been directly compared against
each other, differentially expressed genes may represent
differences in cells of origin of each tumor type rather
than be important for initiation, maintenance, and/or
growth/metastasis of that tumor type. Because cell of
origin is not known for these tumor types, we could not
use in vivo or in vitro derived normal cells as a compar-
ison. Therefore, non-malignant brain tissue, which is a
mix of cells of origin, was utilized to compare against
each tumor type. This approach identified 792 genes
Step 1 Step 2 Step 3 Step 4
TFs
g1
TFs
g1
TFs
g1
DEGs
g1
g2
g3
g7
g5
g3
g7
g5
g3
g7
g5g3
g4
g5
g2 g4     g6 g8 g10
g9
g2 g4     g6 g8 g10
g9
g2 g6 g10
g9g6
g7
g8
Target genes Target genes Target genes
g9
g10
Figure 2 Creation of a minimal transcriptional regulatory network. Step 1: Differentially expressed genes (DEGs) are identified using SAM
based selection. Step 2: Transcription Factors (TFs) and regulatory relationships (i.e. TF - TF) are identified among DEGs by using PAP. Step 3: A
regulatory network is drawn by finding target genes regulated by TFs (i.e. TF - Target) from the DEG set using PAP. Step 4: A minimal network is
generated by identifying targets regulated by more than one transcription factor.
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that showed consistent differential expression between
the reference tissue data and multiple sets of PA tumors
in the training data set, and these 792 genes were also
differentially expressed in the test data set.
Use of network analyses to create a minimal gene
regulatory network
Multiple studies have identified individual gene tran-
scripts that are differentially expressed in PA relative to
other malignant and non-malignant cell populations [4].
In the current study, we identified 792 genes using this
larger sample set. However, to impart higher-order bio-
logical significance to the list of genes we identified and
to select groups of genes from this list that may, as a
network, provide additional insights into the unique
clinical or molecular features of PA, we sought to iden-
tify gene regulatory relationships that comprise networks
unique to this common pediatric astrocytoma histologic
subtype. This approach is distinct from other
approaches that define molecular networks based on
direct or indirect gene-gene interactions [19,20]. Many
previous approaches use existing literature annotation at
the gene and cell biology level, including canonical path-
ways, and heavily depend on human curation of the bio-
logical knowledge in the published literature [21]. A
recent study used the Algorithm for the Reconstruction
of Accurate Cellular Networks (ARACNe), an informa-
tion-theoretic approach, to infer transcriptional net-
works underlying mesenchymal transformation of high
grade gliomas [22-24]. While ARACNe calculates
mutual information between each pair of genes using
expression information and identifies TF-target interac-
tions using annotations from TRANSFAC and Gene
Ontology, it does not employ statistical approaches to
predict TF-target interactions using TF position weight
matrices and phylogenetic footprinting. Therefore, in
the current analysis, we have implemented a novel ana-
lytical method previously developed and described, Pro-
moter Analysis Pipeline (PAP) [25,26]. PAP exhaustively
searches for TF binding sites in the promoter regions of
genes, identifies over-represented binding sites, and pre-
dicts genes in the genome that are most likely regulated
by a set of TFs. PAP is available to the community
through our website (http://bioinformatics.wustl.edu/
webTools/PromoterAnalysis.do).
We melded in silico genome-wide PAP-derived predic-
tions together with an empirically-determined list of dif-
ferentially-expressed gene sets identified by microarray
expression analysis to identify transcription factors (TFs)
that regulate other transcription factors (Figure 2, step
2). Subsequently, the network was expanded to include
TF-target gene relationships (Figure 2, step 3), and was
then pruned to include only those genes regulated by
more than one TF (Figure 2, step 4). This output,
termed the minimal network, represents both the TF
cascade and core TF-target gene relationships that are
predicted to operate in the disease under study.
From the 792 ‘significant genes’ first identified by SAM
analysis of which 197 genes were up-regulated and 595
genes down-regulated (Additional file 1 STable 2), the
minimal PA network is composed of a set of six core TFs
(STAT4, RUNX1, ELK3, LMO2, THRB, and ONECUT2),
twenty-four corresponding target genes, and a total of
fifty-five relationships between them (Figure 3A; the
complete PA network predicted is available as Additional
file 2, SFig 1). Although the way in which these predicted
gene interactions influence PA pathogenesis is not imme-
diately obvious, it is worth noting that the functions of
proteins encoded by several of these individual tran-
scripts have been implicated in a variety of other tumor
types, while RUNX1 and SMOC1 may be more specifi-
cally related to astrocytoma biology [27,28].
Identification of PA-specific and common glial
transcriptional networks
To better understand whether the PA transcriptional
network was specific to this glial tumor type, we gener-
ated analogous networks for oligodendroglioma and
glioblastoma multiforme tumors, and these were com-
pared to the PA minimal network. The comprehensive
oligodendroglioma network that was created through a
similar analysis of oligodendroglioma gene expression
data sets and PAP-generated interactions (step 3 in Fig-
ure 2) is shown in Figure 3B. There are sixteen gene
regulatory interactions among the three TFs (STAT4,
TCF12, and SOX4) and fifteen targets. Compared to the
assembled PA minimal network, the oligodendroglioma
network is less elaborate, probably due to the more lim-
ited gene expression data set available for its generation.
Importantly, there were no genes or relationships shared
between the PA and oligodendroglioma networks. The
lack of overlap between PA and oligodendroglioma net-
works contrasts to other data that suggests the presence
of oligodendroglial-like features in PA tumors [29] and
the expression of oligodendroglial-specific transcription
factors, like SOX10, in astrocytic tumors [30]. However,
common pathological features between PA and oligo-
dendroglioma do not necessarily imply a common histo-
genesis, nor do they preclude the notion that these two
glial tumor types are distinct pathological and genetic
entities.
By comparison, the minimal network assembled for
glioblastoma multiforme included 2,933 total genes,
194 TFs, and 25,038 gene regulatory interactions. This
result no doubt reflects the complexity and heteroge-
neity of the GBM genome [3] and is consistent with
the network generated by ARACNe using high grade
glioma expression data sets [24]. All relationships
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identified in the oligodendroglioma network (Figure
3B) were also represented in the GBM network, sug-
gesting greater similarity between these two tumor
types. Of note, master regulators (C/EBP beta and
delta, STAT3, FOSL2, RUNX1, and bHLH-B2) with
the exception or bHLH-B2 operating in high grade
gliomas that were identified by Carro, et al [24], were
all found in our GBM network as well (Additional file
3, STable 1). In contrast, among the fifty-five relation-
ships in the PA minimal network, forty-one were
shared between PA and glioblastoma multiforme, but
13 were specific to PA (Figure 3C). There were five
individual transcription factor interactions (RUNX1,
STAT4, THRB, LMO2, and ELK3) shared between PA
and GBM, but only one TF interaction, ONECUT2,
was specific to PA. ONECUT2 is a bipartite DNA-
binding domain-containing homeobox gene highly
expressed in the developing mouse nervous system
during embryogenesis, and has been shown to be
important for regulating neural differentiation in Dro-
sophila [25]. Furthermore, ONECUT2 is often methy-
lated or silenced in human cancer, and may be
amenable to methylation-directed therapies [26].
Conclusions
In the current study, we employed only TF-gene interac-
tions to assemble predicted regulatory networks. The
use of this methodological approach illustrates how tra-
ditional, microarray-based gene expression data can be
integrated with a novel TF-gene interaction database
generated from primary genome sequence analysis to
reveal higher-order, cell-specific transcriptional regula-
tory networks. The approach detailed in this report has
significant advantages over conventional microarray
methods aimed at identifying ‘significant’ differential
gene expression. First, many low-grade tumors, like PAs,
harbor few obvious genetic alterations (e.g., oncogenic
mutations, translocations), and the critical changes that
facilitate tumorigenesis and continued growth may
reflect de-regulated gene expression patterns. These lat-
ter alterations may result from “genetic re-program-
ming” due to changes in TF expression, and would only
be uncovered by examining the impact of these changes
in the context of coordinated gene expression patterns.
Second, the ability to extract gene expression patterns is
often limited by the depth of the current scientific lit-
erature knowledgebase, and can be arduous and
a) b)
c)
Figure 3 Minimal transcriptional regulatory networks in gliomas. (A) Minimal network for pilocytic astrocytoma. Transcription factors (TF) are
shown by large solid circles, target genes are shown by small solid circles. Interactions between TF-TF and TF-target are shown by directed
edges. Genes overexpressed in PA relative to non-malignant brain tissue are shown in red, while genes whose expression is lower in PA are
shown in green. (B) Similar relationships depicted in the minimal network assembled from the oligodendroglioma gene expression data set. (C)
Relationships that are unique to PA as compared to the minimal network assembled for GBM.
Deshmukh et al. BMC Medical Genomics 2011, 4:57
http://www.biomedcentral.com/1755-8794/4/57
Page 7 of 9
unenlightening, particularly when candidate gene lists
are large (e.g., 792 genes in this study). The use of the
PAP method represents a more robust approach for
identifying coordinated patterns of gene transcription by
coupling downstream TF target expression levels with a
corresponding TF-gene interaction network based on
sequence-predicted interactions. Lastly, direct measure-
ments of differential TF gene expression are difficult,
particularly by relatively insensitive microarray-based
methods, owning to the inherent low levels of TF gene
expression and the effect that even small changes in TF
levels may have on downstream targets and cell pheno-
type. Further application of the approach presented here
could involve the use of additional genome annotation
derived from TF protein interaction databases, litera-
ture-based gene-gene interaction data, and miRNA-gene
target data. For example, patterns of coordinated gene
expression derived from experimental microarray-based
data could be superimposed upon gene expression regu-
lation modeled as a linear combination of probabilistic
contributions from individual TFs and miRNAs using
multiple regression methods.
Additional material
Additional file 1: The 792 gene set that is differentially expressed in
PAs along with each gene’s expression differences when compared
to the control are shown.
Additional file 2: PA network obtained as a result of step 3 in
Figure 2. Transcription factors (TF) are shown by large solid circles,
target genes are shown by small solid circles. Interactions between TF-TF
and TF-target are shown by directed edges. Genes overexpressed in PA
relative to non-malignant brain tissue are shown in red while genes
whose expression is lower in PA are shown in green.
Additional file 3: Gene regulatory relationships in glioblastoma
multiforme minimal network. The Transcription Factors (TFs) and
respective relationships between their targets are shown.
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